MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies

As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical functions of miRNAs, over the past few decades, the roles of miRNAs in cancer have been actively investigated. Numerous pieces of evidence indi...

Full description

Saved in:
Bibliographic Details
Published inExperimental & molecular medicine Vol. 55; no. 7; pp. 1314 - 1321
Main Authors Kim, Taewan, Croce, Carlo M.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.07.2023
Springer Nature B.V
Nature Publishing Group
생화학분자생물학회
Subjects
631/67/1059
692/308/153
Antineoplastic Agents - therapeutic use
Biomarkers
Biomarkers, Tumor - genetics
Biomedical and Life Sciences
Biomedicine
Cancer research
Cancer therapies
Clinical trials
Diagnosis
Drug development
Drug efficacy
Humans
Medical Biochemistry
Medical research
MicroRNAs
MicroRNAs - genetics
miRNA
Molecular Medicine
Neoplasms - diagnosis
Neoplasms - genetics
Neoplasms - therapy
Review
Review Article
Stem Cells
Therapeutic targets
Tumors
생화학
Online AccessGet full text

Cover

Abstract As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical functions of miRNAs, over the past few decades, the roles of miRNAs in cancer have been actively investigated. Numerous pieces of evidence indicate that miRNAs are pivotal factors in most types of cancer. Recent cancer research focused on miRNAs has identified and characterized a large cohort of miRNAs commonly dysregulated in cancer or exclusively dysregulated in specific types of cancer. These studies have suggested the potential of miRNAs as biomarkers in the diagnosis and prognostication of cancer. Moreover, many of these miRNAs have oncogenic or tumor-suppressive functions. MiRNAs have been the focus of research given their potential clinical applications as therapeutic targets. Currently, various oncology clinical trials using miRNAs in screening, diagnosis, and drug testing are underway. Although clinical trials studying miRNAs in various diseases have been reviewed before, there have been fewer clinical trials related to miRNAs in cancer. Furthermore, updated results of recent preclinical studies and clinical trials of miRNA biomarkers and drugs in cancer are needed. Therefore, this review aims to provide up-to-date information on miRNAs as biomarkers and cancer drugs in clinical trials. Cancer: Clinical trials on microRNAs’ diagnostic and therapeutic potential The discovery of microRNAs' critical role in tumor development has sparked numerous clinical trials focused on evaluating their potential as biomarkers and targets for anti-cancer therapies. Taewan Kim from Shenzhen University, China, and Carlo Croce from The Ohio State University in Columbus, USA, summarize the various ongoing and completed trials aimed at determining whether cancer-linked microRNAs found in blood or tissues can serve as accurate predictors of cancer development or drug efficacy. The researchers discuss the development of drug mimics or inhibitors of specific microRNAs that are now in or nearing human testing as potential anti-cancer therapeutics. Although the research is still in its early stages, the authors envision a future where microRNA-based medicines and diagnostics become routine in cancer patient care, improving personalized treatment strategies and outcomes.
AbstractList As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical functions of miRNAs, over the past few decades, the roles of miRNAs in cancer have been actively investigated. Numerous pieces of evidence indicate that miRNAs are pivotal factors in most types of cancer. Recent cancer research focused on miRNAs has identified and characterized a large cohort of miRNAs commonly dysregulated in cancer or exclusively dysregulated in specific types of cancer. These studies have suggested the potential of miRNAs as biomarkers in the diagnosis and prognostication of cancer. Moreover, many of these miRNAs have oncogenic or tumor-suppressive functions. MiRNAs have been the focus of research given their potential clinical applications as therapeutic targets. Currently, various oncology clinical trials using miRNAs in screening, diagnosis, and drug testing are underway. Although clinical trials studying miRNAs in various diseases have been reviewed before, there have been fewer clinical trials related to miRNAs in cancer. Furthermore, updated results of recent preclinical studies and clinical trials of miRNA biomarkers and drugs in cancer are needed. Therefore, this review aims to provide up-to-date information on miRNAs as biomarkers and cancer drugs in clinical trials.As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical functions of miRNAs, over the past few decades, the roles of miRNAs in cancer have been actively investigated. Numerous pieces of evidence indicate that miRNAs are pivotal factors in most types of cancer. Recent cancer research focused on miRNAs has identified and characterized a large cohort of miRNAs commonly dysregulated in cancer or exclusively dysregulated in specific types of cancer. These studies have suggested the potential of miRNAs as biomarkers in the diagnosis and prognostication of cancer. Moreover, many of these miRNAs have oncogenic or tumor-suppressive functions. MiRNAs have been the focus of research given their potential clinical applications as therapeutic targets. Currently, various oncology clinical trials using miRNAs in screening, diagnosis, and drug testing are underway. Although clinical trials studying miRNAs in various diseases have been reviewed before, there have been fewer clinical trials related to miRNAs in cancer. Furthermore, updated results of recent preclinical studies and clinical trials of miRNA biomarkers and drugs in cancer are needed. Therefore, this review aims to provide up-to-date information on miRNAs as biomarkers and cancer drugs in clinical trials.
As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical functions of miRNAs, over the past few decades, the roles of miRNAs in cancer have been actively investigated. Numerous pieces of evidence indicate that miRNAs are pivotal factors in most types of cancer. Recent cancer research focused on miRNAs has identified and characterized a large cohort of miRNAs commonly dysregulated in cancer or exclusively dysregulated in specific types of cancer. These studies have suggested the potential of miRNAs as biomarkers in the diagnosis and prognostication of cancer. Moreover, many of these miRNAs have oncogenic or tumor-suppressive functions. MiRNAs have been the focus of research given their potential clinical applications as therapeutic targets. Currently, various oncology clinical trials using miRNAs in screening, diagnosis, and drug testing are underway. Although clinical trials studying miRNAs in various diseases have been reviewed before, there have been fewer clinical trials related to miRNAs in cancer. Furthermore, updated results of recent preclinical studies and clinical trials of miRNA biomarkers and drugs in cancer are needed. Therefore, this review aims to provide up-to-date information on miRNAs as biomarkers and cancer drugs in clinical trials.
Abstract As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical functions of miRNAs, over the past few decades, the roles of miRNAs in cancer have been actively investigated. Numerous pieces of evidence indicate that miRNAs are pivotal factors in most types of cancer. Recent cancer research focused on miRNAs has identified and characterized a large cohort of miRNAs commonly dysregulated in cancer or exclusively dysregulated in specific types of cancer. These studies have suggested the potential of miRNAs as biomarkers in the diagnosis and prognostication of cancer. Moreover, many of these miRNAs have oncogenic or tumor-suppressive functions. MiRNAs have been the focus of research given their potential clinical applications as therapeutic targets. Currently, various oncology clinical trials using miRNAs in screening, diagnosis, and drug testing are underway. Although clinical trials studying miRNAs in various diseases have been reviewed before, there have been fewer clinical trials related to miRNAs in cancer. Furthermore, updated results of recent preclinical studies and clinical trials of miRNA biomarkers and drugs in cancer are needed. Therefore, this review aims to provide up-to-date information on miRNAs as biomarkers and cancer drugs in clinical trials.
As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical functions of miRNAs, over the past few decades, the roles of miRNAs in cancer have been actively investigated. Numerous pieces of evidence indicate that miRNAs are pivotal factors in most types of cancer. Recent cancer research focused on miRNAs has identified and characterized a large cohort of miRNAs commonly dysregulated in cancer or exclusively dysregulated in specific types of cancer. These studies have suggested the potential of miRNAs as biomarkers in the diagnosis and prognostication of cancer. Moreover, many of these miRNAs have oncogenic or tumor-suppressive functions. MiRNAs have been the focus of research given their potential clinical applications as therapeutic targets. Currently, various oncology clinical trials using miRNAs in screening, diagnosis, and drug testing are underway. Although clinical trials studying miRNAs in various diseases have been reviewed before, there have been fewer clinical trials related to miRNAs in cancer. Furthermore, updated results of recent preclinical studies and clinical trials of miRNA biomarkers and drugs in cancer are needed. Therefore, this review aims to provide up-to-date information on miRNAs as biomarkers and cancer drugs in clinical trials.Cancer: Clinical trials on microRNAs’ diagnostic and therapeutic potentialThe discovery of microRNAs' critical role in tumor development has sparked numerous clinical trials focused on evaluating their potential as biomarkers and targets for anti-cancer therapies. Taewan Kim from Shenzhen University, China, and Carlo Croce from The Ohio State University in Columbus, USA, summarize the various ongoing and completed trials aimed at determining whether cancer-linked microRNAs found in blood or tissues can serve as accurate predictors of cancer development or drug efficacy. The researchers discuss the development of drug mimics or inhibitors of specific microRNAs that are now in or nearing human testing as potential anti-cancer therapeutics. Although the research is still in its early stages, the authors envision a future where microRNA-based medicines and diagnostics become routine in cancer patient care, improving personalized treatment strategies and outcomes.
As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical functions of miRNAs, over the past few decades, the roles of miRNAs in cancer have been actively investigated. Numerous pieces of evidence indicate that miRNAs are pivotal factors in most types of cancer. Recent cancer research focused on miRNAs has identified and characterized a large cohort of miRNAs commonly dysregulated in cancer or exclusively dysregulated in specific types of cancer. These studies have suggested the potential of miRNAs as biomarkers in the diagnosis and prognostication of cancer. Moreover, many of these miRNAs have oncogenic or tumor-suppressive functions. MiRNAs have been the focus of research given their potential clinical applications as therapeutic targets. Currently, various oncology clinical trials using miRNAs in screening, diagnosis, and drug testing are underway. Although clinical trials studying miRNAs in various diseases have been reviewed before, there have been fewer clinical trials related to miRNAs in cancer. Furthermore, updated results of recent preclinical studies and clinical trials of miRNA biomarkers and drugs in cancer are needed. Therefore, this review aims to provide up-to-date information on miRNAs as biomarkers and cancer drugs in clinical trials. Cancer: Clinical trials on microRNAs’ diagnostic and therapeutic potential The discovery of microRNAs' critical role in tumor development has sparked numerous clinical trials focused on evaluating their potential as biomarkers and targets for anti-cancer therapies. Taewan Kim from Shenzhen University, China, and Carlo Croce from The Ohio State University in Columbus, USA, summarize the various ongoing and completed trials aimed at determining whether cancer-linked microRNAs found in blood or tissues can serve as accurate predictors of cancer development or drug efficacy. The researchers discuss the development of drug mimics or inhibitors of specific microRNAs that are now in or nearing human testing as potential anti-cancer therapeutics. Although the research is still in its early stages, the authors envision a future where microRNA-based medicines and diagnostics become routine in cancer patient care, improving personalized treatment strategies and outcomes.
As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical functions of miRNAs, over the past few decades, the roles of miRNAs in cancer have been actively investigated. Numerous pieces of evidence indicate that miRNAs are pivotal factors in most types of cancer. Recent cancer research focused on miRNAs has identified and characterized a large cohort of miRNAs commonly dysregulated in cancer or exclusively dysregulated in specific types of cancer. These studies have suggested the potential of miRNAs as biomarkers in the diagnosis and prognostication of cancer. Moreover, many of these miRNAs have oncogenic or tumor-suppressive functions. MiRNAs have been the focus of research given their potential clinical applications as therapeutic targets. Currently, various oncology clinical trials using miRNAs in screening, diagnosis, and drug testing are underway. Although clinical trials studying miRNAs in various diseases have been reviewed before, there have been fewer clinical trials related to miRNAs in cancer. Furthermore, updated results of recent preclinical studies and clinical trials of miRNA biomarkers and drugs in cancer are needed. Therefore, this review aims to provide up-to-date information on miRNAs as biomarkers and cancer drugs in clinical trials. KCI Citation Count: 0
As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical functions of miRNAs, over the past few decades, the roles of miRNAs in cancer have been actively investigated. Numerous pieces of evidence indicate that miRNAs are pivotal factors in most types of cancer. Recent cancer research focused on miRNAs has identified and characterized a large cohort of miRNAs commonly dysregulated in cancer or exclusively dysregulated in specific types of cancer. These studies have suggested the potential of miRNAs as biomarkers in the diagnosis and prognostication of cancer. Moreover, many of these miRNAs have oncogenic or tumor-suppressive functions. MiRNAs have been the focus of research given their potential clinical applications as therapeutic targets. Currently, various oncology clinical trials using miRNAs in screening, diagnosis, and drug testing are underway. Although clinical trials studying miRNAs in various diseases have been reviewed before, there have been fewer clinical trials related to miRNAs in cancer. Furthermore, updated results of recent preclinical studies and clinical trials of miRNA biomarkers and drugs in cancer are needed. Therefore, this review aims to provide up-to-date information on miRNAs as biomarkers and cancer drugs in clinical trials. The discovery of microRNAs' critical role in tumor development has sparked numerous clinical trials focused on evaluating their potential as biomarkers and targets for anti-cancer therapies. Taewan Kim from Shenzhen University, China, and Carlo Croce from The Ohio State University in Columbus, USA, summarize the various ongoing and completed trials aimed at determining whether cancer-linked microRNAs found in blood or tissues can serve as accurate predictors of cancer development or drug efficacy. The researchers discuss the development of drug mimics or inhibitors of specific microRNAs that are now in or nearing human testing as potential anti-cancer therapeutics. Although the research is still in its early stages, the authors envision a future where microRNA-based medicines and diagnostics become routine in cancer patient care, improving personalized treatment strategies and outcomes.
Author Kim, Taewan
Croce, Carlo M.
Author_xml – sequence: 1
  givenname: Taewan
  orcidid: 0000-0002-7202-009X
  surname: Kim
  fullname: Kim, Taewan
  email: taewankim@szu.edu.cn
  organization: Department of Anatomy, Histology & Developmental Biology, International Cancer Center, School of Medicine, Shenzhen University
– sequence: 2
  givenname: Carlo M.
  surname: Croce
  fullname: Croce, Carlo M.
  email: carlo.croce@osumc.edu
  organization: Department of Cancer Biology and Genetics, The Ohio State University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37430087$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002984781$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9kltrFDEYhgep2IP-AS9kwBsRRnOaHLyRpXhYqBVKvQ6Z5JtptrPJmswK_fdmd1pte1EISfjyvC9vku-4OggxQFW9xugDRlR-zJgQwRtEaIMwalGjnlVHBCnScIbpwb39YXWc8woh0jLBXlSHVDCKkBRH1fkPb1O8OF98qqcEweXah9qOPnhrxlLyZsx17GtrgoVUO2-GELPPtQmunq4gmc1NnadkJhg85JfV874o4NXtelL9-vrl8vR7c_bz2_J0cdZYzsjUcCxdp6DDFJSxxLIytQQks33bIiwx560D6whhQloseWeFBMJ7EIo4DvSkej_7htTra-t1NH6_DlFfJ724uFxqjIhUhOMCL2fYRbPSm-TXJt3sFftCTIM2afJ2BG1cKy0HJKHrGUihgLuWmTKEYoyh4vV59tpsuzU4C6HcfXxg-vAk-KsS6k9JQ1XR7xze3Tqk-HsLedJrny2MowkQt1kTydoCU9YW9O0jdBW3KZSH3VGMUSYFLdSb-5H-Zbn75ALIGSg_nXOCXls_mcnHXUI_lmi7dFLP_aRLP-l9P2lVpOSR9M79SRGdRbnAYYD0P_YTqr_cmttF
CitedBy_id crossref_primary_10_1016_j_azn_2025_01_002
crossref_primary_10_1016_j_jbc_2024_107344
crossref_primary_10_1016_j_biopha_2024_116165
crossref_primary_10_1039_D4RA07080A
crossref_primary_10_3390_nu16020258
crossref_primary_10_31083_j_fbl2903099
crossref_primary_10_1016_j_bioadv_2024_214160
crossref_primary_10_1186_s12929_024_01013_w
crossref_primary_10_3390_cimb46070402
crossref_primary_10_3390_genes16030330
crossref_primary_10_1007_s12015_025_10866_z
crossref_primary_10_1016_j_heliyon_2024_e30646
crossref_primary_10_1007_s00432_024_05882_4
crossref_primary_10_1186_s12885_024_13259_6
crossref_primary_10_3923_ajbs_2025_516_532
crossref_primary_10_3892_ol_2024_14798
crossref_primary_10_3390_cancers16112027
crossref_primary_10_1186_s12964_023_01330_x
crossref_primary_10_3390_ijms252111384
crossref_primary_10_1016_j_neuroscience_2024_06_032
crossref_primary_10_32604_biocell_2024_055505
crossref_primary_10_2217_epi_2023_0363
crossref_primary_10_3390_cancers15235557
crossref_primary_10_3390_cells13060545
crossref_primary_10_1016_j_ymthe_2024_11_023
crossref_primary_10_3389_fmolb_2024_1353547
crossref_primary_10_1038_s41598_024_75557_0
crossref_primary_10_1089_hum_2024_113
crossref_primary_10_1186_s13018_024_05291_w
crossref_primary_10_3390_plants14030325
crossref_primary_10_1007_s10142_024_01409_9
crossref_primary_10_1016_j_heliyon_2024_e33763
crossref_primary_10_1021_acs_nanolett_5c00089
crossref_primary_10_1155_2024_9436238
crossref_primary_10_1016_j_xcrp_2024_101801
crossref_primary_10_1007_s11033_024_10208_1
crossref_primary_10_3390_ijms252312839
crossref_primary_10_4240_wjgs_v16_i2_289
crossref_primary_10_3390_ijms25179393
crossref_primary_10_3390_ijms252413335
crossref_primary_10_3390_diagnostics14131450
crossref_primary_10_1038_s41598_025_92537_0
crossref_primary_10_1186_s40364_024_00689_4
crossref_primary_10_3390_jcm13226960
crossref_primary_10_3390_ncrna11020027
crossref_primary_10_1002_bmm2_12127
crossref_primary_10_1016_j_cellsig_2024_111263
crossref_primary_10_1038_s41392_024_01889_y
crossref_primary_10_1038_s41598_025_91007_x
crossref_primary_10_3390_cancers16091698
crossref_primary_10_3390_biomedicines12092072
crossref_primary_10_1093_bjd_ljae492
crossref_primary_10_1016_j_yexcr_2025_114482
crossref_primary_10_1089_ars_2023_0482
crossref_primary_10_1002_1878_0261_13744
crossref_primary_10_1007_s10142_024_01519_4
crossref_primary_10_1021_acsami_4c17191
crossref_primary_10_3390_genes16020180
crossref_primary_10_3390_ijms26020733
crossref_primary_10_1016_j_mcp_2023_101940
crossref_primary_10_1016_j_biopha_2024_116275
crossref_primary_10_23736_S2724_542X_25_03254_7
crossref_primary_10_7555_JBR_37_20230245
crossref_primary_10_3390_genes16030262
crossref_primary_10_1007_s11033_024_09439_z
crossref_primary_10_1002_admt_202301570
crossref_primary_10_31083_j_fbl2901044
crossref_primary_10_1002_adma_202419651
crossref_primary_10_3390_ijms25137395
crossref_primary_10_1038_s41420_024_02193_y
crossref_primary_10_1371_journal_pcbi_1012446
crossref_primary_10_3892_ijo_2024_5703
crossref_primary_10_1016_j_ncrna_2025_02_006
crossref_primary_10_1007_s11033_024_10205_4
crossref_primary_10_3390_ijms252413679
crossref_primary_10_1007_s11427_024_2819_y
crossref_primary_10_1186_s13019_024_03322_5
crossref_primary_10_3390_genes15050574
crossref_primary_10_1002_smtd_202400349
crossref_primary_10_2340_1651_226X_2024_27976
crossref_primary_10_3390_biology14010043
crossref_primary_10_1002_EXP_20230165
crossref_primary_10_1016_j_ijpharm_2024_125117
crossref_primary_10_3390_cancers16040766
crossref_primary_10_1007_s12010_024_05123_x
crossref_primary_10_1136_jitc_2024_009774
crossref_primary_10_3390_ijms26031278
crossref_primary_10_1039_D4NA00660G
crossref_primary_10_2174_187460981701240229094013
crossref_primary_10_3390_ijms26051844
crossref_primary_10_1016_j_freeradbiomed_2024_11_023
crossref_primary_10_1016_j_prp_2024_155707
crossref_primary_10_1093_nar_gkae017
crossref_primary_10_1016_j_heliyon_2024_e39931
crossref_primary_10_1002_mog2_93
crossref_primary_10_20945_2359_4292_2024_0073
crossref_primary_10_1007_s10006_023_01199_7
crossref_primary_10_3390_cancers15204910
crossref_primary_10_1007_s12192_023_01371_8
crossref_primary_10_3390_genes15070905
crossref_primary_10_1038_s41392_024_02035_4
crossref_primary_10_1016_j_critrevonc_2024_104361
crossref_primary_10_1039_D4LC00340C
crossref_primary_10_3390_v16121945
crossref_primary_10_1080_10408347_2024_2329229
crossref_primary_10_1016_j_mrfmmm_2025_111903
crossref_primary_10_1038_s42003_024_06488_9
crossref_primary_10_1016_j_snb_2024_135389
crossref_primary_10_21320_2500_2139_2024_17_2_154_165
crossref_primary_10_1021_acsabm_4c01861
crossref_primary_10_1186_s43556_024_00194_y
crossref_primary_10_1016_j_tips_2023_12_002
crossref_primary_10_1007_s11033_024_09981_w
crossref_primary_10_1039_D3SD00340J
crossref_primary_10_1002_ange_202407039
crossref_primary_10_1038_s41422_024_00975_8
crossref_primary_10_3390_pharmaceutics16080986
crossref_primary_10_1038_s42004_024_01182_7
crossref_primary_10_1186_s13027_024_00615_1
crossref_primary_10_1080_00032719_2024_2360696
crossref_primary_10_3390_cells12212559
crossref_primary_10_1186_s12929_025_01121_1
crossref_primary_10_1038_s41467_024_52707_6
crossref_primary_10_1038_s12276_023_01051_8
crossref_primary_10_1360_TB_2024_0523
crossref_primary_10_1016_j_heliyon_2024_e39489
crossref_primary_10_1097_MEG_0000000000002903
crossref_primary_10_2147_IJN_S471900
crossref_primary_10_3390_ijms25042178
crossref_primary_10_1016_j_ymthe_2024_12_045
crossref_primary_10_1016_j_ejphar_2025_177494
crossref_primary_10_3390_ncrna11010012
crossref_primary_10_1002_smll_202406439
crossref_primary_10_1016_j_envres_2024_119496
crossref_primary_10_1021_acs_analchem_4c05256
crossref_primary_10_3390_cells14020084
crossref_primary_10_3390_cells13161383
crossref_primary_10_1007_s00210_024_03675_7
crossref_primary_10_3390_diagnostics13182893
crossref_primary_10_62347_NPLT8946
crossref_primary_10_1016_j_addr_2024_115448
crossref_primary_10_1016_j_bbrc_2024_149724
crossref_primary_10_3390_ijms25010119
crossref_primary_10_1002_anie_202407039
crossref_primary_10_3390_ijms25115865
crossref_primary_10_1016_j_molmed_2024_07_004
crossref_primary_10_1016_j_cellsig_2025_111756
crossref_primary_10_1002_jbt_70156
crossref_primary_10_1016_j_reth_2025_01_019
crossref_primary_10_1016_j_hlife_2024_11_002
Cites_doi 10.1093/jmcb/mju003
10.1155/2021/3408937
10.1038/mtna.2014.47
10.3892/mmr.2016.5603
10.1016/j.ejphar.2019.03.018
10.1016/j.canlet.2020.08.004
10.21037/pcm-21-28
10.1111/bjh.15547
10.1016/j.omtn.2021.01.020
10.1186/s13046-016-0432-x
10.1158/1078-0432.CCR-20-3139
10.4161/rna.8.5.16324
10.1136/gutjnl-2019-319826
10.1073/pnas.0804549105
10.3389/fimmu.2018.02491
10.1038/nbt.1618
10.3389/fendo.2018.00402
10.1007/s00535-017-1408-0
10.1038/emm.2015.57
10.1021/acscentsci.2c00748
10.1093/carcin/bgv106
10.1038/nature05939
10.1128/AAC.04220-14
10.1038/s41416-020-0802-1
10.1073/pnas.0602266103
10.1038/emm.2014.51
10.1186/s12885-017-3875-3
10.1016/j.bios.2022.114041
10.1016/j.ebiom.2022.104304
10.1093/annonc/mdw392.16
10.1182/blood-2010-01-264812
10.1186/s12866-021-02315-x
10.3389/fonc.2022.858892
10.3748/wjg.v20.i37.13258
10.1016/0092-8674(93)90530-4
10.3390/cells9010008
10.1166/jbn.2014.1795
10.2147/OTT.S181706
10.1016/j.gpb.2012.07.005
10.1007/s40265-022-01745-9
10.3390/biomedicines10010156
10.1007/s10555-017-9724-7
10.1007/s00438-010-0556-1
10.1038/s12276-020-00510-w
10.1038/s12276-022-00916-8
10.3390/ijms231911389
10.3389/fgene.2019.00478
10.1016/j.biopha.2015.08.009
10.1016/j.genrep.2018.06.012
10.1084/jem.20110235
10.1016/j.cell.2012.05.003
10.2147/OTT.S238665
10.1007/s11095-012-0679-7
10.1038/nature02871
10.1002/jcp.28368
10.1073/pnas.242606799
10.18632/oncotarget.27327
10.1038/nrc1997
10.1038/nsmb.1762
10.3389/fmicb.2021.641322
10.1038/nrg2634
10.3389/fonc.2020.00472
10.1016/j.ijbiomac.2017.10.154
10.3390/ijms23052805
10.1038/nrd4140
10.1073/pnas.1301693110
10.1002/jcp.26060
10.1038/emm.2015.17
10.1158/0008-5472.CAN-07-1484
10.1093/carcin/bgz183
10.1148/radiology.181.1.1887040
10.1002/jmv.24230
10.1159/000511691
10.1002/tox.23160
10.1016/j.molcel.2007.05.017
10.1016/S1470-2045(17)30621-6
10.3892/ijo.2013.1896
10.1186/s12935-019-0875-1
10.1177/1533033820905825
10.1038/nature03677
10.3390/cancers14215414
10.1016/j.cell.2011.02.013
10.1089/nat.2020.0871
10.18632/oncotarget.27894
10.1016/j.ejca.2008.09.037
10.1016/j.semcancer.2020.12.025
10.1002/wrna.1248
10.3390/cancers13071526
10.1186/s12885-019-5731-0
10.1038/s41419-019-1685-z
10.1038/cr.2012.36
10.1016/0092-8674(93)90529-Y
10.1002/pros.1131
10.1073/pnas.0506654102
10.3390/ijms21031136
10.1371/journal.pone.0265948
10.1016/j.jare.2020.08.012
10.1111/wrr.12660
10.1089/scd.2011.0695
10.1186/1423-0127-20-99
10.1038/nature06174
10.1038/s41467-019-11918-y
ContentType Journal Article
Copyright The Author(s) 2023
2023. The Author(s).
The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2023
– notice: 2023. The Author(s).
– notice: The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
ACYCR
DOI 10.1038/s12276-023-01050-9
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Database
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef

Publicly Available Content Database

MEDLINE
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
EISSN 2092-6413
EndPage 1321
ExternalDocumentID oai_kci_go_kr_ARTI_10289261
oai_doaj_org_article_ad58c6e08ebf4e879e6d54a54a794440
PMC10394030
37430087
10_1038_s12276_023_01050_9
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
  grantid: CA197706
  funderid: https://doi.org/10.13039/100000054
– fundername: Shenzhen Science and Technology Innovation Commission
  grantid: 20200812161921001
  funderid: https://doi.org/10.13039/501100010877
– fundername: National Natural Science Foundation of China (National Science Foundation of China)
  grantid: 82073120
  funderid: https://doi.org/10.13039/501100001809
– fundername: NCI NIH HHS
  grantid: R35 CA197706
– fundername: ;
  grantid: CA197706
– fundername: ;
  grantid: 20200812161921001
– fundername: ;
  grantid: 82073120
GroupedDBID ---
0R~
29G
2WC
3V.
5-W
53G
5GY
7X7
87B
88E
8FE
8FH
8FI
8FJ
8JR
9ZL
AAJSJ
ABUWG
ACGFO
ACGFS
ACPRK
ACSMW
ACYCR
ADBBV
AENEX
AFKRA
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BBNVY
BENPR
BHPHI
BPHCQ
BVXVI
C1A
C6C
CCPQU
DIK
DU5
E3Z
EBLON
EBS
EF.
EJD
EMOBN
F5P
FYUFA
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
LK8
M1P
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
TR2
UKHRP
W2D
XSB
AASML
AAYXX
CITATION
OVT
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
7XB
8FK
AARCD
AZQEC
DWQXO
GNUQQ
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
AAADF
AFGXO
ID FETCH-LOGICAL-c642t-618db9eb13e9ac2c4ac252e84cf550181665decd22478c186bc78e26fe792d6e3
IEDL.DBID DOA
ISSN 2092-6413
1226-3613
IngestDate Sun Jan 07 03:19:18 EST 2024
Wed Aug 27 01:29:51 EDT 2025
Thu Aug 21 18:42:09 EDT 2025
Fri Jul 11 11:09:35 EDT 2025
Wed Aug 13 09:13:13 EDT 2025
Mon Jul 21 05:59:51 EDT 2025
Tue Jul 01 04:10:32 EDT 2025
Thu Apr 24 23:04:14 EDT 2025
Fri Feb 21 02:40:06 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Language English
License 2023. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c642t-618db9eb13e9ac2c4ac252e84cf550181665decd22478c186bc78e26fe792d6e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0002-7202-009X
OpenAccessLink https://doaj.org/article/ad58c6e08ebf4e879e6d54a54a794440
PMID 37430087
PQID 2844434873
PQPubID 2041975
PageCount 8
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_10289261
doaj_primary_oai_doaj_org_article_ad58c6e08ebf4e879e6d54a54a794440
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10394030
proquest_miscellaneous_2845103345
proquest_journals_2844434873
pubmed_primary_37430087
crossref_citationtrail_10_1038_s12276_023_01050_9
crossref_primary_10_1038_s12276_023_01050_9
springer_journals_10_1038_s12276_023_01050_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-07-01
PublicationDateYYYYMMDD 2023-07-01
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-01
  day: 01
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: United States
– name: Seoul
PublicationTitle Experimental & molecular medicine
PublicationTitleAbbrev Exp Mol Med
PublicationTitleAlternate Exp Mol Med
PublicationYear 2023
Publisher Nature Publishing Group UK
Springer Nature B.V
Nature Publishing Group
생화학분자생물학회
Publisher_xml – name: Nature Publishing Group UK
– name: Springer Nature B.V
– name: Nature Publishing Group
– name: 생화학분자생물학회
References Ma (CR48) 2020; 13
Costinean (CR82) 2006; 103
Mihanfar, Fattahi, Nejabati (CR55) 2017; 234
Li (CR43) 2019; 19
Smolarz, Durczyński, Romanowicz, Szyłło, Hogendorf (CR58) 2022; 23
Sun (CR37) 2017; 53
Ji, Chen (CR105) 2012; 22
Anastasiadou (CR83) 2021; 27
Chioccioli (CR25) 2022; 85
Wang (CR62) 2015; 47
Patel (CR21) 2013; 110
Cimmino (CR76) 2005; 102
van Zandwijk (CR78) 2017; 18
Cheng, Qin, Zhi, Wang, Qin (CR36) 2018; 107
Croce (CR74) 2009; 10
Li, Kowdley (CR14) 2012; 10
Fang (CR39) 2018; 54
Lee (CR22) 2019; 10
Jiang, Zhi, Ma, Zhou (CR46) 2019; 23
Bayraktar, Van Roosbroeck (CR80) 2017; 37
Wang (CR88) 2012; 21
Pan, Hong, Li, Meng, Xiao (CR67) 2021; 53
Rokavec, Li, Jiang, Hermeking (CR70) 2014; 6
Hong (CR73) 2020; 122
Sheedy, Medarova (CR97) 2018; 8
Lee, Feinbaum, Ambros (CR3) 1993; 75
Miyoshi, Miyoshi, Siomi (CR5) 2010; 284
Mirahmadi (CR103) 2021; 2021
Zhou, Ding, Jin, Li (CR49) 2020; 87
Bakhti, Latifi-Navid (CR30) 2021; 21
O’Brien, Hayder, Zayed, Peng (CR107) 2018; 9
Liang, He (CR98) 2021; 4
Wightman, Ha, Ruvkun (CR2) 1993; 75
Zhou (CR68) 2015; 47
Cheng, Ma, Tan, Zhang (CR61) 2014; 46
Quirico, Orso (CR101) 2020; 3
Witten, Slack (CR81) 2019; 41
Nakano, Yamada, Miyazawa, Yoshida (CR87) 2013; 42
To (CR52) 2013; 20
Ma, Teruya-Feldstein, Weinberg (CR92) 2007; 449
Kim, Croce (CR4) 2021; 75
Seto (CR84) 2018; 183
Yoo (CR94) 2014; 10
Radanova (CR63) 2022; 10
Ji, Yang (CR27) 2020; 21
Chakraborty, Sharma, Sharma, Lee (CR15) 2021; 28
He (CR9) 2007; 447
Raver-Shapira (CR10) 2007; 26
Ottosen (CR20) 2014; 59
Huang (CR38) 2017; 17
Tehler, Høyland-Kroghsbo, Lund (CR91) 2011; 8
Meyer Kate (CR66) 2012; 149
Ramaiah (CR77) 2018; 12
Ambros (CR1) 2004; 431
Doebele (CR17) 2010; 115
Dong, Boyd, Frierson (CR75) 2001; 49
van den Bosch (CR90) 2021; 23
Telford (CR89) 2021; 12
Sung (CR26) 2020; 69
Xian, Tang, Wu, Huang (CR40) 2018; 11
Khordadmehr, Shahbazi, Sadreddini, Baradaran (CR85) 2019; 234
Jame-Chenarboo, Ng, Macdonald, Mahal (CR6) 2022; 8
Wu, Ma, Zhu (CR34) 2016; 14
Yanaka, Muramatsu, Uetake, Kozaki, Inazawa (CR33) 2015; 36
Ovcharenko, Kelnar, Johnson, Leng, Brown (CR86) 2007; 67
Kim (CR11) 2011; 208
Peltier, Kelnar, Bader (CR72) 2016; 27
Mitchell (CR108) 2008; 105
Song (CR42) 2019; 852
Yang, Zhou, Liu, Ling, Ji (CR29) 2021; 12
Guan, Ma, Yang, Yu, Yao (CR50) 2021; 36
Lu, Yao, Sun, Li (CR59) 2022; 203
Hanahan, Weinberg (CR110) 2011; 144
Abplanalp (CR18) 2020; 30
Ma (CR93) 2010; 28
Ling, Fabbri, Calin (CR71) 2013; 12
Russo (CR28) 2014; 20
Yigit, Moore, Medarova (CR95) 2012; 29
Zhang (CR102) 2022; 23
Zografos (CR104) 2019; 10
Lee (CR19) 2015; 87
Kai, Pasquinelli (CR106) 2010; 17
Kalkusova, Taborska, Stakheev, Smrz (CR79) 2022; 14
Weissleder (CR96) 1991; 181
Iorio, Casalini, Tagliabue, Ménard, Croce (CR51) 2008; 44
Kim (CR65) 2023; 55
Peng (CR41) 2018; 40
Zheng (CR47) 2020; 19
Yue (CR32) 2017; 9
Yuan (CR44) 2019; 10
Yang (CR109) 2018; 9
Penumetcha (CR31) 2021; 13
Robertson, Yigit (CR53) 2014; 5
Laitinen (CR7) 2022; 17
Calin, Croce (CR13) 2006; 6
Gallant‐Behm (CR16) 2018; 26
O’Donnell, Wentzel, Zeller, Dang, Mendell (CR12) 2005; 435
Misso (CR69) 2014; 3
Li, Li, Mu, Guo, Deng (CR45) 2019; 19
Dehghanzadeh, Jadidi-Niaragh, Gharibi, Yousefi (CR54) 2015; 74
Ma (CR60) 2022; 12
Liao, Jung, Kim (CR64) 2020; 494
Hanna, Hossain, Kocerha (CR24) 2019; 10
CR100
Fan, Ren, Yang, Liu, Zhang (CR35) 2016; 35
Romano, Acunzo, Nana-Sinkam (CR99) 2021; 13
Calin (CR8) 2002; 99
Bais, Gansevoort, Meijer (CR23) 2022; 82
Jiao (CR56) 2020; 9
Guo (CR57) 2020; 10
HJ Peltier (1050_CR72) 2016; 27
1050_CR100
Y Mirahmadi (1050_CR103) 2021; 2021
CM Croce (1050_CR74) 2009; 10
R Bayraktar (1050_CR80) 2017; 37
G Romano (1050_CR99) 2021; 13
H Nakano (1050_CR87) 2013; 42
MV Iorio (1050_CR51) 2008; 44
J Wang (1050_CR88) 2012; 21
F Russo (1050_CR28) 2014; 20
D Tehler (1050_CR91) 2011; 8
C Zhang (1050_CR102) 2022; 23
H Yue (1050_CR32) 2017; 9
PS Mitchell (1050_CR108) 2008; 105
P Laitinen (1050_CR7) 2022; 17
N van Zandwijk (1050_CR78) 2017; 18
J-T Dong (1050_CR75) 2001; 49
J Huang (1050_CR38) 2017; 17
A Mihanfar (1050_CR55) 2017; 234
J Hanna (1050_CR24) 2019; 10
Q Guo (1050_CR57) 2020; 10
GA Calin (1050_CR13) 2006; 6
C Chakraborty (1050_CR15) 2021; 28
L He (1050_CR9) 2007; 447
E Zografos (1050_CR104) 2019; 10
F Jame-Chenarboo (1050_CR6) 2022; 8
Z Fang (1050_CR39) 2018; 54
NM Robertson (1050_CR53) 2014; 5
M Khordadmehr (1050_CR85) 2019; 234
H Ling (1050_CR71) 2013; 12
RC Lee (1050_CR3) 1993; 75
B Ma (1050_CR48) 2020; 13
KA O’Donnell (1050_CR12) 2005; 435
T-H Lee (1050_CR19) 2015; 87
J Ji (1050_CR27) 2020; 21
R Weissleder (1050_CR96) 1991; 181
E Anastasiadou (1050_CR83) 2021; 27
T Kim (1050_CR11) 2011; 208
MV Yigit (1050_CR95) 2012; 29
Y Liao (1050_CR64) 2020; 494
F Wang (1050_CR62) 2015; 47
B Guan (1050_CR50) 2021; 36
MTJ van den Bosch (1050_CR90) 2021; 23
L Ji (1050_CR105) 2012; 22
V Patel (1050_CR21) 2013; 110
SZ Bakhti (1050_CR30) 2021; 21
D Fan (1050_CR35) 2016; 35
G Misso (1050_CR69) 2014; 3
C Cheng (1050_CR36) 2018; 107
B Wightman (1050_CR2) 1993; 75
L Ma (1050_CR93) 2010; 28
K Jiang (1050_CR46) 2019; 23
L Quirico (1050_CR101) 2020; 3
ZS Kai (1050_CR106) 2010; 17
L Witten (1050_CR81) 2019; 41
S Costinean (1050_CR82) 2006; 103
M Rokavec (1050_CR70) 2014; 6
Y Peng (1050_CR41) 2018; 40
EC Lee (1050_CR22) 2019; 10
T Bais (1050_CR23) 2022; 82
M Ma (1050_CR60) 2022; 12
D Zhou (1050_CR68) 2015; 47
N Yang (1050_CR109) 2018; 9
B Smolarz (1050_CR58) 2022; 23
X Lu (1050_CR59) 2022; 203
H Song (1050_CR42) 2019; 852
Y Li (1050_CR43) 2019; 19
N Raver-Shapira (1050_CR10) 2007; 26
A Cimmino (1050_CR76) 2005; 102
M Chioccioli (1050_CR25) 2022; 85
W Li (1050_CR45) 2019; 19
BJ Telford (1050_CR89) 2021; 12
W Zhou (1050_CR49) 2020; 87
D Meyer Kate (1050_CR66) 2012; 149
D Hanahan (1050_CR110) 2011; 144
J Yuan (1050_CR44) 2019; 10
G-L Sun (1050_CR37) 2017; 53
K Miyoshi (1050_CR5) 2010; 284
AG Seto (1050_CR84) 2018; 183
Z Cheng (1050_CR61) 2014; 46
T Kim (1050_CR4) 2021; 75
Y Li (1050_CR14) 2012; 10
X Jiao (1050_CR56) 2020; 9
HS Kim (1050_CR65) 2023; 55
MJ Ramaiah (1050_CR77) 2018; 12
J Yang (1050_CR29) 2021; 12
D Ovcharenko (1050_CR86) 2007; 67
P Sheedy (1050_CR97) 2018; 8
GA Calin (1050_CR8) 2002; 99
K Wu (1050_CR34) 2016; 14
DS Hong (1050_CR73) 2020; 122
KK To (1050_CR52) 2013; 20
R Dehghanzadeh (1050_CR54) 2015; 74
L Ma (1050_CR92) 2007; 449
CL Gallant‐Behm (1050_CR16) 2018; 26
WT Abplanalp (1050_CR18) 2020; 30
M Radanova (1050_CR63) 2022; 10
K Kalkusova (1050_CR79) 2022; 14
V Ambros (1050_CR1) 2004; 431
C Doebele (1050_CR17) 2010; 115
X Pan (1050_CR67) 2021; 53
JJY Sung (1050_CR26) 2020; 69
SS Penumetcha (1050_CR31) 2021; 13
J O’Brien (1050_CR107) 2018; 9
J Zheng (1050_CR47) 2020; 19
L Liang (1050_CR98) 2021; 4
S Ottosen (1050_CR20) 2014; 59
B Yoo (1050_CR94) 2014; 10
X Xian (1050_CR40) 2018; 11
Y Yanaka (1050_CR33) 2015; 36
References_xml – volume: 9
  start-page: 3654
  year: 2017
  end-page: 3664
  ident: CR32
  article-title: MIR-519d suppresses the gastric cancer epithelial-mesenchymal transition via Twist1 and inhibits Wnt/β-catenin signaling pathway
  publication-title: Am. J. Transl. Res.
– volume: 6
  start-page: 214
  year: 2014
  end-page: 230
  ident: CR70
  article-title: The p53/miR-34 axis in development and disease
  publication-title: J. Mol. Cell Biol.
  doi: 10.1093/jmcb/mju003
– volume: 40
  start-page: 3323
  year: 2018
  end-page: 3334
  ident: CR41
  article-title: Inhibition of miR‑194 suppresses the Wnt/β‑catenin signalling pathway in gastric cancer
  publication-title: Oncol. Rep.
– volume: 2021
  start-page: 1
  year: 2021
  end-page: 25
  ident: CR103
  article-title: MicroRNAs as Biomarkers for Early Diagnosis, Prognosis, and Therapeutic Targeting of Ovarian Cancer
  publication-title: J. Oncol.
  doi: 10.1155/2021/3408937
– volume: 3
  start-page: e194
  year: 2014
  ident: CR69
  article-title: Mir-34: A New Weapon Against Cancer?
  publication-title: Mol. Ther. - Nucleic Acids
  doi: 10.1038/mtna.2014.47
– volume: 14
  start-page: 3421
  year: 2016
  end-page: 3428
  ident: CR34
  article-title: miR-483-5p promotes growth, invasion and self-renewal of gastric cancer stem cells by Wnt/β-catenin signaling
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2016.5603
– volume: 852
  start-page: 189
  year: 2019
  end-page: 197
  ident: CR42
  article-title: BRD4 promotes the stemness of gastric cancer cells via attenuating miR-216a-3p-mediated inhibition of Wnt/β-catenin signaling
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2019.03.018
– volume: 494
  start-page: 88
  year: 2020
  end-page: 93
  ident: CR64
  article-title: A-to-I RNA editing as a tuner of noncoding RNAs in cancer
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2020.08.004
– volume: 4
  start-page: 33
  year: 2021
  end-page: 33
  ident: CR98
  article-title: A narrative review of microRNA therapeutics: understanding the future of microRNA research
  publication-title: Precis. Cancer Med.
  doi: 10.21037/pcm-21-28
– volume: 183
  start-page: 428
  year: 2018
  end-page: 444
  ident: CR84
  article-title: Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma
  publication-title: Br. J. Haematol.
  doi: 10.1111/bjh.15547
– volume: 23
  start-page: 1161
  year: 2021
  end-page: 1171
  ident: CR90
  article-title: Transcriptome-wide analysis reveals insight into tumor suppressor functions of 1B3, a novel synthetic miR-193a-3p mimic
  publication-title: Mol. Ther. - Nucleic Acids
  doi: 10.1016/j.omtn.2021.01.020
– volume: 35
  start-page: 177
  year: 2016
  ident: CR35
  article-title: Upregulation of miR-501-5p activates the wnt/β-catenin signaling pathway and enhances stem cell-like phenotype in gastric cancer
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-016-0432-x
– volume: 27
  start-page: 1139
  year: 2021
  end-page: 1149
  ident: CR83
  article-title: Cobomarsen, an Oligonucleotide Inhibitor of miR-155, Slows DLBCL Tumor Cell Growth In Vitro and In Vivo
  publication-title: Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-3139
– volume: 8
  start-page: 728
  year: 2011
  end-page: 734
  ident: CR91
  article-title: The miR-10 microRNA precursor family
  publication-title: RNA Biol.
  doi: 10.4161/rna.8.5.16324
– volume: 69
  start-page: 1572
  year: 2020
  end-page: 1580
  ident: CR26
  article-title: Gastric microbes associated with gastric inflammation, atrophy and intestinal metaplasia 1 year after Helicobacter pylori eradication
  publication-title: Gut
  doi: 10.1136/gutjnl-2019-319826
– volume: 105
  start-page: 10513
  year: 2008
  end-page: 10518
  ident: CR108
  article-title: Circulating microRNAs as stable blood-based markers for cancer detection
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.0804549105
– volume: 9
  start-page: 2491
  year: 2018
  ident: CR109
  article-title: MicroRNAs: Pleiotropic Regulators in the Tumor Microenvironment
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.02491
– volume: 28
  start-page: 341
  year: 2010
  end-page: 347
  ident: CR93
  article-title: Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.1618
– volume: 9
  start-page: 402
  year: 2018
  ident: CR107
  article-title: Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation
  publication-title: Front. Endocrinol.
  doi: 10.3389/fendo.2018.00402
– volume: 53
  start-page: 725
  year: 2017
  end-page: 739
  ident: CR37
  article-title: miR-324-3p promotes gastric cancer development by activating Smad4-mediated Wnt/beta-catenin signaling pathway
  publication-title: J. Gastroenterol.
  doi: 10.1007/s00535-017-1408-0
– volume: 23
  start-page: 9890
  year: 2019
  end-page: 9899
  ident: CR46
  article-title: Long non-coding RNA TOB1-AS1 modulates cell proliferation, apoptosis, migration and invasion through miR-23a/NEU1 axis via Wnt/b-catenin pathway in gastric cancer
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 47
  start-page: e182
  year: 2015
  end-page: e182
  ident: CR68
  article-title: DNMT1 mediates chemosensitivity by reducing methylation of miRNA-20a promoter in glioma cells
  publication-title: Exp. Mol. Med.
  doi: 10.1038/emm.2015.57
– volume: 8
  start-page: 1527
  year: 2022
  end-page: 1536
  ident: CR6
  article-title: High-Throughput Analysis Reveals miRNA Upregulating α-2,6-Sialic Acid through Direct miRNA–mRNA Interactions
  publication-title: ACS Cent. Sci.
  doi: 10.1021/acscentsci.2c00748
– ident: CR100
– volume: 36
  start-page: 1363
  year: 2015
  end-page: 1371
  ident: CR33
  article-title: induces epithelial–mesenchymal transition through the activation of WNT signaling pathway in gastric cancer
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgv106
– volume: 447
  start-page: 1130
  year: 2007
  end-page: 1134
  ident: CR9
  article-title: A microRNA component of the p53 tumour suppressor network
  publication-title: Nature
  doi: 10.1038/nature05939
– volume: 59
  start-page: 599
  year: 2014
  end-page: 608
  ident: CR20
  article-title: In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122
  publication-title: Antimicrobial Agents Chemother.
  doi: 10.1128/AAC.04220-14
– volume: 122
  start-page: 1630
  year: 2020
  end-page: 1637
  ident: CR73
  article-title: Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-020-0802-1
– volume: 103
  start-page: 7024
  year: 2006
  end-page: 7029
  ident: CR82
  article-title: Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in Eμ-miR155 transgenic mice
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.0602266103
– volume: 46
  start-page: e112
  year: 2014
  end-page: e112
  ident: CR61
  article-title: MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2
  publication-title: Exp. Mol. Med.
  doi: 10.1038/emm.2014.51
– volume: 17
  year: 2017
  ident: CR38
  article-title: miR-302b inhibits tumorigenesis by targeting EphA2 via Wnt/ β-catenin/EMT signaling cascade in gastric cancer
  publication-title: BMC Cancer
  doi: 10.1186/s12885-017-3875-3
– volume: 203
  start-page: 114041
  year: 2022
  ident: CR59
  article-title: Plasmon-enhanced biosensors for microRNA analysis and cancer diagnosis
  publication-title: Biosens. Bioelectron.
  doi: 10.1016/j.bios.2022.114041
– volume: 85
  start-page: 104304
  year: 2022
  ident: CR25
  article-title: A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis
  publication-title: eBioMedicine
  doi: 10.1016/j.ebiom.2022.104304
– volume: 27
  start-page: vi531
  year: 2016
  ident: CR72
  article-title: Effects of MRX34, a liposomal miR-34 mimic, on target gene expression in human white blood cells (hWBCs): qRT-PCR results from a first-in-human trial of microRNA cancer therapy
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdw392.16
– volume: 115
  start-page: 4944
  year: 2010
  end-page: 4950
  ident: CR17
  article-title: Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells
  publication-title: Blood
  doi: 10.1182/blood-2010-01-264812
– volume: 21
  year: 2021
  ident: CR30
  article-title: Interplay and cooperation of Helicobacter pylori and gut microbiota in gastric carcinogenesis
  publication-title: BMC Microbiol.
  doi: 10.1186/s12866-021-02315-x
– volume: 12
  start-page: 858892
  year: 2022
  ident: CR60
  article-title: The Role and Mechanism of microRNA-1224 in Human Cancer
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.858892
– volume: 20
  start-page: 13258
  year: 2014
  ident: CR28
  article-title: Probiotics against neoplastic transformation of gastric mucosa: Effects on cell proliferation and polyamine metabolism
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v20.i37.13258
– volume: 54
  start-page: 733
  year: 2018
  end-page: 743
  ident: CR39
  article-title: miR‑381 and miR‑489 suppress cell proliferation and invasion by targeting CUL4B via the Wnt/β‑catenin pathway in gastric cancer
  publication-title: Int. J. Oncol.
– volume: 75
  start-page: 855
  year: 1993
  end-page: 862
  ident: CR2
  article-title: Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90530-4
– volume: 9
  start-page: 8
  year: 2020
  ident: CR56
  article-title: microRNA: The Impact on Cancer Stemness and Therapeutic Resistance
  publication-title: Cells
  doi: 10.3390/cells9010008
– volume: 10
  start-page: 1114
  year: 2014
  end-page: 1122
  ident: CR94
  article-title: Design of Nanodrugs for miRNA Targeting in Tumor Cells
  publication-title: J. Biomed. Nanotechnol.
  doi: 10.1166/jbn.2014.1795
– volume: 11
  start-page: 7503
  year: 2018
  end-page: 7512
  ident: CR40
  article-title: miR-23b-3p and miR-130a-5p affect cell growth, migration and invasion by targeting CB1R via the Wnt/β-catenin signaling pathway in gastric carcinoma
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S181706
– volume: 10
  start-page: 246
  year: 2012
  end-page: 253
  ident: CR14
  article-title: MicroRNAs in Common Human Diseases
  publication-title: Genom. Proteom. Bioinforma.
  doi: 10.1016/j.gpb.2012.07.005
– volume: 82
  start-page: 1095
  year: 2022
  end-page: 1115
  ident: CR23
  article-title: Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease
  publication-title: Drugs
  doi: 10.1007/s40265-022-01745-9
– volume: 10
  start-page: 156
  year: 2022
  ident: CR63
  article-title: Single Nucleotide Polymorphisms in microRNA Genes and Colorectal Cancer Risk and Prognosis
  publication-title: Biomedicines
  doi: 10.3390/biomedicines10010156
– volume: 37
  start-page: 33
  year: 2017
  end-page: 44
  ident: CR80
  article-title: miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
  publication-title: Cancer Metastasis Rev.
  doi: 10.1007/s10555-017-9724-7
– volume: 284
  start-page: 95
  year: 2010
  end-page: 103
  ident: CR5
  article-title: Many ways to generate microRNA-like small RNAs: non-canonical pathways for microRNA production
  publication-title: Mol. Genet. Genom.
  doi: 10.1007/s00438-010-0556-1
– volume: 53
  start-page: 91
  year: 2021
  end-page: 102
  ident: CR67
  article-title: METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner
  publication-title: Exp. Mol. Med.
  doi: 10.1038/s12276-020-00510-w
– volume: 55
  start-page: 95
  year: 2023
  end-page: 107
  ident: CR65
  article-title: ADAR1-dependent miR-3144-3p editing simultaneously induces MSI2 expression and suppresses SLC38A4 expression in liver cancer
  publication-title: Exp. Mol. Med.
  doi: 10.1038/s12276-022-00916-8
– volume: 23
  start-page: 11389
  year: 2022
  ident: CR102
  article-title: Overview of MicroRNAs as Diagnostic and Prognostic Biomarkers for High-Incidence Cancers in 2021
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms231911389
– volume: 10
  start-page: 478
  year: 2019
  ident: CR24
  article-title: The Potential for microRNA Therapeutics and Clinical Research
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2019.00478
– volume: 74
  start-page: 191
  year: 2015
  end-page: 199
  ident: CR54
  article-title: MicroRNA-induced drug resistance in gastric cancer
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2015.08.009
– volume: 12
  start-page: 149
  year: 2018
  end-page: 164
  ident: CR77
  article-title: Functions and epigenetic aspects of miR-15/16: Possible future cancer therapeutics
  publication-title: Gene Rep.
  doi: 10.1016/j.genrep.2018.06.012
– volume: 3
  start-page: 117
  year: 2020
  end-page: 139
  ident: CR101
  article-title: The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies
  publication-title: Cancer Drug Resist.
– volume: 208
  start-page: 875
  year: 2011
  end-page: 883
  ident: CR11
  article-title: p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20110235
– volume: 149
  start-page: 1635
  year: 2012
  end-page: 1646
  ident: CR66
  article-title: Comprehensive Analysis of mRNA Methylation Reveals Enrichment in 3′ UTRs and near Stop Codons
  publication-title: Cell
  doi: 10.1016/j.cell.2012.05.003
– volume: 13
  start-page: 3411
  year: 2020
  end-page: 3423
  ident: CR48
  article-title: Effects of miR-330-3p on Invasion, Migration and EMT of Gastric Cancer Cells by Targeting PRRX1-Mediated Wnt/β-Catenin Signaling Pathway
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S238665
– volume: 29
  start-page: 1180
  year: 2012
  end-page: 1188
  ident: CR95
  article-title: Magnetic Nanoparticles for Cancer Diagnosis and Therapy
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-012-0679-7
– volume: 431
  start-page: 350
  year: 2004
  end-page: 355
  ident: CR1
  article-title: The functions of animal microRNAs
  publication-title: Nature
  doi: 10.1038/nature02871
– volume: 234
  start-page: 16861
  year: 2019
  end-page: 16872
  ident: CR85
  article-title: miR-193: A new weapon against cancer
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.28368
– volume: 99
  start-page: 15524
  year: 2002
  end-page: 15529
  ident: CR8
  article-title: Nonlinear partial differential equations and applications: Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.242606799
– volume: 10
  start-page: 7156
  year: 2019
  end-page: 7178
  ident: CR104
  article-title: Prognostic role of microRNAs in breast cancer: a systematic review
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.27327
– volume: 6
  start-page: 857
  year: 2006
  end-page: 866
  ident: CR13
  article-title: MicroRNA signatures in human cancers
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc1997
– volume: 17
  start-page: 5
  year: 2010
  end-page: 10
  ident: CR106
  article-title: MicroRNA assassins: factors that regulate the disappearance of miRNAs
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/nsmb.1762
– volume: 12
  start-page: 641322
  year: 2021
  ident: CR29
  article-title: Role of the Gastric Microbiome in Gastric Cancer: From Carcinogenesis to Treatment
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2021.641322
– volume: 10
  start-page: 704
  year: 2009
  end-page: 714
  ident: CR74
  article-title: Causes and consequences of microRNA dysregulation in cancer
  publication-title: Nat. Rev. Genet.
  doi: 10.1038/nrg2634
– volume: 10
  start-page: 472
  year: 2020
  ident: CR57
  article-title: The Role of Exosomal microRNA in Cancer Drug Resistance
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.00472
– volume: 107
  start-page: 2620
  year: 2018
  end-page: 2629
  ident: CR36
  article-title: Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a
  publication-title: Int. J. Biol. Macromol.
  doi: 10.1016/j.ijbiomac.2017.10.154
– volume: 23
  start-page: 2805
  year: 2022
  ident: CR58
  article-title: miRNAs in Cancer (Review of Literature)
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms23052805
– volume: 12
  start-page: 847
  year: 2013
  end-page: 865
  ident: CR71
  article-title: MicroRNAs and other non-coding RNAs as targets for anticancer drug development
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd4140
– volume: 110
  start-page: 10765
  year: 2013
  end-page: 10770
  ident: CR21
  article-title: miR-17∼92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.1301693110
– volume: 234
  start-page: 3180
  year: 2017
  end-page: 3191
  ident: CR55
  article-title: MicroRNA‐mediated drug resistance in ovarian cancer
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.26060
– volume: 47
  start-page: e162
  year: 2015
  end-page: e162
  ident: CR62
  article-title: miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy
  publication-title: Exp. Mol. Med.
  doi: 10.1038/emm.2015.17
– volume: 67
  start-page: 10782
  year: 2007
  end-page: 10788
  ident: CR86
  article-title: Genome-Scale MicroRNA and Small Interfering RNA Screens Identify Small RNA Modulators of TRAIL-Induced Apoptosis Pathway
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-07-1484
– volume: 41
  start-page: 2
  year: 2019
  end-page: 7
  ident: CR81
  article-title: miR-155 as a novel clinical target for hematological malignancies
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgz183
– volume: 181
  start-page: 245
  year: 1991
  end-page: 249
  ident: CR96
  article-title: Polyclonal human immunoglobulin G labeled with polymeric iron oxide: antibody MR imaging
  publication-title: Radiology
  doi: 10.1148/radiology.181.1.1887040
– volume: 8
  start-page: 1674
  year: 2018
  end-page: 1688
  ident: CR97
  article-title: The fundamental role of miR-10b in metastatic cancer
  publication-title: Am. J. Cancer Res.
– volume: 87
  start-page: 1722
  year: 2015
  end-page: 1726
  ident: CR19
  article-title: MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.24230
– volume: 87
  start-page: 327
  year: 2020
  end-page: 337
  ident: CR49
  article-title: miR-6838-5p Affects Cell Growth, Migration, and Invasion by Targeting GPRIN3 via the Wnt/β-Catenin Signaling Pathway in Gastric Cancer
  publication-title: Pathobiology
  doi: 10.1159/000511691
– volume: 36
  start-page: 1640
  year: 2021
  end-page: 1653
  ident: CR50
  article-title: LncRNA NCK1‐AS1 exerts oncogenic property in gastric cancer by targeting the miR‐22‐3p/BCL9 axis to activate the Wnt/β‐catenin signaling
  publication-title: Environ. Toxicol.
  doi: 10.1002/tox.23160
– volume: 26
  start-page: 731
  year: 2007
  end-page: 743
  ident: CR10
  article-title: Transcriptional Activation of miR-34a Contributes to p53-Mediated Apoptosis
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2007.05.017
– volume: 18
  start-page: 1386
  year: 2017
  end-page: 1396
  ident: CR78
  article-title: Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30621-6
– volume: 42
  start-page: 1875
  year: 2013
  end-page: 1882
  ident: CR87
  article-title: Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2013.1896
– volume: 19
  year: 2019
  ident: CR45
  article-title: MiR-503 suppresses cell proliferation and invasion of gastric cancer by targeting HMGA2 and inactivating WNT signaling pathway
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-019-0875-1
– volume: 19
  start-page: 1533033820905825
  year: 2020
  ident: CR47
  article-title: Hypoxia Activates SOX5/Wnt/β-Catenin Signaling by Suppressing MiR-338-3p in Gastric Cancer
  publication-title: Technol. Cancer Res. Treat.
  doi: 10.1177/1533033820905825
– volume: 435
  start-page: 839
  year: 2005
  end-page: 843
  ident: CR12
  article-title: c-Myc-regulated microRNAs modulate E2F1 expression
  publication-title: Nature
  doi: 10.1038/nature03677
– volume: 14
  start-page: 5414
  year: 2022
  ident: CR79
  article-title: The Role of miR-155 in Antitumor Immunity
  publication-title: Cancers
  doi: 10.3390/cancers14215414
– volume: 13
  start-page: e20483
  year: 2021
  ident: CR31
  article-title: The Efficacy of Probiotics in the Management of Helicobacter Pylori: A Systematic Review
  publication-title: Cureus
– volume: 144
  start-page: 646
  year: 2011
  end-page: 674
  ident: CR110
  article-title: Hallmarks of cancer: the next Generation
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 30
  start-page: 335
  year: 2020
  end-page: 345
  ident: CR18
  article-title: Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study
  publication-title: Nucleic Acid Ther.
  doi: 10.1089/nat.2020.0871
– volume: 12
  start-page: 422
  year: 2021
  end-page: 439
  ident: CR89
  article-title: Multi-modal effects of 1B3, a novel synthetic miR-193a-3p mimic, support strong potential for therapeutic intervention in oncology
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.27894
– volume: 44
  start-page: 2753
  year: 2008
  end-page: 2759
  ident: CR51
  article-title: MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2008.09.037
– volume: 75
  start-page: 3
  year: 2021
  end-page: 14
  ident: CR4
  article-title: MicroRNA and ER stress in cancer
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2020.12.025
– volume: 5
  start-page: 823
  year: 2014
  end-page: 833
  ident: CR53
  article-title: The role of microRNA in resistance to breast cancer therapy
  publication-title: Wiley Interdiscip. Rev.: RNA
  doi: 10.1002/wrna.1248
– volume: 13
  start-page: 1526
  year: 2021
  ident: CR99
  article-title: microRNAs as Novel Therapeutics in Cancer
  publication-title: Cancers
  doi: 10.3390/cancers13071526
– volume: 19
  year: 2019
  ident: CR43
  article-title: Aberrantly expressed miR-188-5p promotes gastric cancer metastasis by activating Wnt/β-catenin signaling
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-5731-0
– volume: 10
  start-page: 454
  year: 2019
  ident: CR44
  article-title: MIR17HG-miR-18a/19a axis, regulated by interferon regulatory factor-1, promotes gastric cancer metastasis via Wnt/β-catenin signalling
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-019-1685-z
– volume: 22
  start-page: 624
  year: 2012
  end-page: 636
  ident: CR105
  article-title: Regulation of small RNA stability: methylation and beyond
  publication-title: Cell Res.
  doi: 10.1038/cr.2012.36
– volume: 75
  start-page: 843
  year: 1993
  end-page: 854
  ident: CR3
  article-title: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90529-Y
– volume: 49
  start-page: 166
  year: 2001
  end-page: 171
  ident: CR75
  article-title: Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer
  publication-title: Prostate
  doi: 10.1002/pros.1131
– volume: 102
  start-page: 13944
  year: 2005
  end-page: 13949
  ident: CR76
  article-title: miR-15 and miR-16 induce apoptosis by targeting BCL2
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.0506654102
– volume: 21
  start-page: 1136
  year: 2020
  ident: CR27
  article-title: Using Probiotics as Supplementation for Helicobacter pylori Antibiotic Therapy
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms21031136
– volume: 17
  start-page: e0265948
  year: 2022
  ident: CR7
  article-title: Nuclear microRNA-466c regulates Vegfa expression in response to hypoxia
  publication-title: PLOS ONE
  doi: 10.1371/journal.pone.0265948
– volume: 28
  start-page: 127
  year: 2021
  end-page: 138
  ident: CR15
  article-title: Therapeutic advances of miRNAs: A preclinical and clinical update
  publication-title: J. Adv. Res.
  doi: 10.1016/j.jare.2020.08.012
– volume: 26
  start-page: 311
  year: 2018
  end-page: 323
  ident: CR16
  article-title: A synthetic microRNA‐92a inhibitor (MRG‐110) accelerates angiogenesis and wound healing in diabetic and nondiabetic wounds
  publication-title: Wound Repair Regener.
  doi: 10.1111/wrr.12660
– volume: 21
  start-page: 2508
  year: 2012
  end-page: 2519
  ident: CR88
  article-title: MicroRNA-193 Pro-Proliferation Effects for Bone Mesenchymal Stem Cells After Low-Level Laser Irradiation Treatment Through Inhibitor of Growth Family, Member 5
  publication-title: Stem Cells Dev.
  doi: 10.1089/scd.2011.0695
– volume: 20
  year: 2013
  ident: CR52
  article-title: MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy
  publication-title: J. Biomed. Sci.
  doi: 10.1186/1423-0127-20-99
– volume: 449
  start-page: 682
  year: 2007
  end-page: 688
  ident: CR92
  article-title: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer
  publication-title: Nature
  doi: 10.1038/nature06174
– volume: 10
  year: 2019
  ident: CR22
  article-title: Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-11918-y
– volume: 102
  start-page: 13944
  year: 2005
  ident: 1050_CR76
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.0506654102
– volume: 10
  year: 2019
  ident: 1050_CR22
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-11918-y
– volume: 36
  start-page: 1640
  year: 2021
  ident: 1050_CR50
  publication-title: Environ. Toxicol.
  doi: 10.1002/tox.23160
– volume: 30
  start-page: 335
  year: 2020
  ident: 1050_CR18
  publication-title: Nucleic Acid Ther.
  doi: 10.1089/nat.2020.0871
– volume: 37
  start-page: 33
  year: 2017
  ident: 1050_CR80
  publication-title: Cancer Metastasis Rev.
  doi: 10.1007/s10555-017-9724-7
– volume: 107
  start-page: 2620
  year: 2018
  ident: 1050_CR36
  publication-title: Int. J. Biol. Macromol.
  doi: 10.1016/j.ijbiomac.2017.10.154
– volume: 20
  year: 2013
  ident: 1050_CR52
  publication-title: J. Biomed. Sci.
  doi: 10.1186/1423-0127-20-99
– volume: 82
  start-page: 1095
  year: 2022
  ident: 1050_CR23
  publication-title: Drugs
  doi: 10.1007/s40265-022-01745-9
– volume: 26
  start-page: 311
  year: 2018
  ident: 1050_CR16
  publication-title: Wound Repair Regener.
  doi: 10.1111/wrr.12660
– volume: 10
  start-page: 454
  year: 2019
  ident: 1050_CR44
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-019-1685-z
– volume: 122
  start-page: 1630
  year: 2020
  ident: 1050_CR73
  publication-title: Br. J. Cancer
  doi: 10.1038/s41416-020-0802-1
– volume: 19
  year: 2019
  ident: 1050_CR43
  publication-title: BMC Cancer
  doi: 10.1186/s12885-019-5731-0
– volume: 103
  start-page: 7024
  year: 2006
  ident: 1050_CR82
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.0602266103
– volume: 10
  start-page: 704
  year: 2009
  ident: 1050_CR74
  publication-title: Nat. Rev. Genet.
  doi: 10.1038/nrg2634
– volume: 6
  start-page: 214
  year: 2014
  ident: 1050_CR70
  publication-title: J. Mol. Cell Biol.
  doi: 10.1093/jmcb/mju003
– volume: 13
  start-page: e20483
  year: 2021
  ident: 1050_CR31
  publication-title: Cureus
– volume: 12
  start-page: 858892
  year: 2022
  ident: 1050_CR60
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2022.858892
– volume: 53
  start-page: 91
  year: 2021
  ident: 1050_CR67
  publication-title: Exp. Mol. Med.
  doi: 10.1038/s12276-020-00510-w
– volume: 36
  start-page: 1363
  year: 2015
  ident: 1050_CR33
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgv106
– volume: 10
  start-page: 156
  year: 2022
  ident: 1050_CR63
  publication-title: Biomedicines
  doi: 10.3390/biomedicines10010156
– volume: 6
  start-page: 857
  year: 2006
  ident: 1050_CR13
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc1997
– volume: 115
  start-page: 4944
  year: 2010
  ident: 1050_CR17
  publication-title: Blood
  doi: 10.1182/blood-2010-01-264812
– volume: 20
  start-page: 13258
  year: 2014
  ident: 1050_CR28
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v20.i37.13258
– volume: 17
  year: 2017
  ident: 1050_CR38
  publication-title: BMC Cancer
  doi: 10.1186/s12885-017-3875-3
– volume: 28
  start-page: 127
  year: 2021
  ident: 1050_CR15
  publication-title: J. Adv. Res.
  doi: 10.1016/j.jare.2020.08.012
– volume: 53
  start-page: 725
  year: 2017
  ident: 1050_CR37
  publication-title: J. Gastroenterol.
  doi: 10.1007/s00535-017-1408-0
– volume: 144
  start-page: 646
  year: 2011
  ident: 1050_CR110
  publication-title: Cell
  doi: 10.1016/j.cell.2011.02.013
– volume: 19
  year: 2019
  ident: 1050_CR45
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-019-0875-1
– volume: 431
  start-page: 350
  year: 2004
  ident: 1050_CR1
  publication-title: Nature
  doi: 10.1038/nature02871
– volume: 12
  start-page: 641322
  year: 2021
  ident: 1050_CR29
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2021.641322
– volume: 234
  start-page: 3180
  year: 2017
  ident: 1050_CR55
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.26060
– volume: 13
  start-page: 1526
  year: 2021
  ident: 1050_CR99
  publication-title: Cancers
  doi: 10.3390/cancers13071526
– volume: 99
  start-page: 15524
  year: 2002
  ident: 1050_CR8
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.242606799
– volume: 54
  start-page: 733
  year: 2018
  ident: 1050_CR39
  publication-title: Int. J. Oncol.
– volume: 494
  start-page: 88
  year: 2020
  ident: 1050_CR64
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2020.08.004
– volume: 105
  start-page: 10513
  year: 2008
  ident: 1050_CR108
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.0804549105
– volume: 8
  start-page: 1527
  year: 2022
  ident: 1050_CR6
  publication-title: ACS Cent. Sci.
  doi: 10.1021/acscentsci.2c00748
– volume: 87
  start-page: 1722
  year: 2015
  ident: 1050_CR19
  publication-title: J. Med. Virol.
  doi: 10.1002/jmv.24230
– volume: 69
  start-page: 1572
  year: 2020
  ident: 1050_CR26
  publication-title: Gut
  doi: 10.1136/gutjnl-2019-319826
– volume: 5
  start-page: 823
  year: 2014
  ident: 1050_CR53
  publication-title: Wiley Interdiscip. Rev.: RNA
  doi: 10.1002/wrna.1248
– volume: 49
  start-page: 166
  year: 2001
  ident: 1050_CR75
  publication-title: Prostate
  doi: 10.1002/pros.1131
– volume: 75
  start-page: 855
  year: 1993
  ident: 1050_CR2
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90530-4
– volume: 35
  start-page: 177
  year: 2016
  ident: 1050_CR35
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-016-0432-x
– volume: 27
  start-page: 1139
  year: 2021
  ident: 1050_CR83
  publication-title: Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res.
  doi: 10.1158/1078-0432.CCR-20-3139
– volume: 149
  start-page: 1635
  year: 2012
  ident: 1050_CR66
  publication-title: Cell
  doi: 10.1016/j.cell.2012.05.003
– volume: 10
  start-page: 478
  year: 2019
  ident: 1050_CR24
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2019.00478
– volume: 85
  start-page: 104304
  year: 2022
  ident: 1050_CR25
  publication-title: eBioMedicine
  doi: 10.1016/j.ebiom.2022.104304
– volume: 9
  start-page: 2491
  year: 2018
  ident: 1050_CR109
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.02491
– volume: 17
  start-page: e0265948
  year: 2022
  ident: 1050_CR7
  publication-title: PLOS ONE
  doi: 10.1371/journal.pone.0265948
– volume: 23
  start-page: 11389
  year: 2022
  ident: 1050_CR102
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms231911389
– volume: 11
  start-page: 7503
  year: 2018
  ident: 1050_CR40
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S181706
– volume: 183
  start-page: 428
  year: 2018
  ident: 1050_CR84
  publication-title: Br. J. Haematol.
  doi: 10.1111/bjh.15547
– ident: 1050_CR100
– volume: 8
  start-page: 728
  year: 2011
  ident: 1050_CR91
  publication-title: RNA Biol.
  doi: 10.4161/rna.8.5.16324
– volume: 22
  start-page: 624
  year: 2012
  ident: 1050_CR105
  publication-title: Cell Res.
  doi: 10.1038/cr.2012.36
– volume: 10
  start-page: 7156
  year: 2019
  ident: 1050_CR104
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.27327
– volume: 29
  start-page: 1180
  year: 2012
  ident: 1050_CR95
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-012-0679-7
– volume: 4
  start-page: 33
  year: 2021
  ident: 1050_CR98
  publication-title: Precis. Cancer Med.
  doi: 10.21037/pcm-21-28
– volume: 47
  start-page: e162
  year: 2015
  ident: 1050_CR62
  publication-title: Exp. Mol. Med.
  doi: 10.1038/emm.2015.17
– volume: 447
  start-page: 1130
  year: 2007
  ident: 1050_CR9
  publication-title: Nature
  doi: 10.1038/nature05939
– volume: 75
  start-page: 3
  year: 2021
  ident: 1050_CR4
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2020.12.025
– volume: 12
  start-page: 847
  year: 2013
  ident: 1050_CR71
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/nrd4140
– volume: 42
  start-page: 1875
  year: 2013
  ident: 1050_CR87
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2013.1896
– volume: 21
  year: 2021
  ident: 1050_CR30
  publication-title: BMC Microbiol.
  doi: 10.1186/s12866-021-02315-x
– volume: 41
  start-page: 2
  year: 2019
  ident: 1050_CR81
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgz183
– volume: 75
  start-page: 843
  year: 1993
  ident: 1050_CR3
  publication-title: Cell
  doi: 10.1016/0092-8674(93)90529-Y
– volume: 44
  start-page: 2753
  year: 2008
  ident: 1050_CR51
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2008.09.037
– volume: 3
  start-page: 117
  year: 2020
  ident: 1050_CR101
  publication-title: Cancer Drug Resist.
– volume: 9
  start-page: 8
  year: 2020
  ident: 1050_CR56
  publication-title: Cells
  doi: 10.3390/cells9010008
– volume: 449
  start-page: 682
  year: 2007
  ident: 1050_CR92
  publication-title: Nature
  doi: 10.1038/nature06174
– volume: 110
  start-page: 10765
  year: 2013
  ident: 1050_CR21
  publication-title: Proc. Natl Acad. Sci.
  doi: 10.1073/pnas.1301693110
– volume: 10
  start-page: 472
  year: 2020
  ident: 1050_CR57
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2020.00472
– volume: 21
  start-page: 1136
  year: 2020
  ident: 1050_CR27
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms21031136
– volume: 12
  start-page: 422
  year: 2021
  ident: 1050_CR89
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.27894
– volume: 14
  start-page: 3421
  year: 2016
  ident: 1050_CR34
  publication-title: Mol. Med. Rep.
  doi: 10.3892/mmr.2016.5603
– volume: 2021
  start-page: 1
  year: 2021
  ident: 1050_CR103
  publication-title: J. Oncol.
  doi: 10.1155/2021/3408937
– volume: 55
  start-page: 95
  year: 2023
  ident: 1050_CR65
  publication-title: Exp. Mol. Med.
  doi: 10.1038/s12276-022-00916-8
– volume: 9
  start-page: 3654
  year: 2017
  ident: 1050_CR32
  publication-title: Am. J. Transl. Res.
– volume: 13
  start-page: 3411
  year: 2020
  ident: 1050_CR48
  publication-title: OncoTargets Ther.
  doi: 10.2147/OTT.S238665
– volume: 208
  start-page: 875
  year: 2011
  ident: 1050_CR11
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20110235
– volume: 23
  start-page: 1161
  year: 2021
  ident: 1050_CR90
  publication-title: Mol. Ther. - Nucleic Acids
  doi: 10.1016/j.omtn.2021.01.020
– volume: 28
  start-page: 341
  year: 2010
  ident: 1050_CR93
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt.1618
– volume: 10
  start-page: 1114
  year: 2014
  ident: 1050_CR94
  publication-title: J. Biomed. Nanotechnol.
  doi: 10.1166/jbn.2014.1795
– volume: 203
  start-page: 114041
  year: 2022
  ident: 1050_CR59
  publication-title: Biosens. Bioelectron.
  doi: 10.1016/j.bios.2022.114041
– volume: 59
  start-page: 599
  year: 2014
  ident: 1050_CR20
  publication-title: Antimicrobial Agents Chemother.
  doi: 10.1128/AAC.04220-14
– volume: 181
  start-page: 245
  year: 1991
  ident: 1050_CR96
  publication-title: Radiology
  doi: 10.1148/radiology.181.1.1887040
– volume: 23
  start-page: 2805
  year: 2022
  ident: 1050_CR58
  publication-title: Int. J. Mol. Sci.
  doi: 10.3390/ijms23052805
– volume: 18
  start-page: 1386
  year: 2017
  ident: 1050_CR78
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(17)30621-6
– volume: 19
  start-page: 153303382090582
  year: 2020
  ident: 1050_CR47
  publication-title: Technol. Cancer Res. Treat.
  doi: 10.1177/1533033820905825
– volume: 27
  start-page: vi531
  year: 2016
  ident: 1050_CR72
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdw392.16
– volume: 87
  start-page: 327
  year: 2020
  ident: 1050_CR49
  publication-title: Pathobiology
  doi: 10.1159/000511691
– volume: 12
  start-page: 149
  year: 2018
  ident: 1050_CR77
  publication-title: Gene Rep.
  doi: 10.1016/j.genrep.2018.06.012
– volume: 40
  start-page: 3323
  year: 2018
  ident: 1050_CR41
  publication-title: Oncol. Rep.
– volume: 17
  start-page: 5
  year: 2010
  ident: 1050_CR106
  publication-title: Nat. Struct. Mol. Biol.
  doi: 10.1038/nsmb.1762
– volume: 10
  start-page: 246
  year: 2012
  ident: 1050_CR14
  publication-title: Genom. Proteom. Bioinforma.
  doi: 10.1016/j.gpb.2012.07.005
– volume: 47
  start-page: e182
  year: 2015
  ident: 1050_CR68
  publication-title: Exp. Mol. Med.
  doi: 10.1038/emm.2015.57
– volume: 21
  start-page: 2508
  year: 2012
  ident: 1050_CR88
  publication-title: Stem Cells Dev.
  doi: 10.1089/scd.2011.0695
– volume: 9
  start-page: 402
  year: 2018
  ident: 1050_CR107
  publication-title: Front. Endocrinol.
  doi: 10.3389/fendo.2018.00402
– volume: 74
  start-page: 191
  year: 2015
  ident: 1050_CR54
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2015.08.009
– volume: 284
  start-page: 95
  year: 2010
  ident: 1050_CR5
  publication-title: Mol. Genet. Genom.
  doi: 10.1007/s00438-010-0556-1
– volume: 435
  start-page: 839
  year: 2005
  ident: 1050_CR12
  publication-title: Nature
  doi: 10.1038/nature03677
– volume: 23
  start-page: 9890
  year: 2019
  ident: 1050_CR46
  publication-title: Eur. Rev. Med. Pharmacol. Sci.
– volume: 14
  start-page: 5414
  year: 2022
  ident: 1050_CR79
  publication-title: Cancers
  doi: 10.3390/cancers14215414
– volume: 26
  start-page: 731
  year: 2007
  ident: 1050_CR10
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2007.05.017
– volume: 8
  start-page: 1674
  year: 2018
  ident: 1050_CR97
  publication-title: Am. J. Cancer Res.
– volume: 67
  start-page: 10782
  year: 2007
  ident: 1050_CR86
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-07-1484
– volume: 46
  start-page: e112
  year: 2014
  ident: 1050_CR61
  publication-title: Exp. Mol. Med.
  doi: 10.1038/emm.2014.51
– volume: 852
  start-page: 189
  year: 2019
  ident: 1050_CR42
  publication-title: Eur. J. Pharmacol.
  doi: 10.1016/j.ejphar.2019.03.018
– volume: 3
  start-page: e194
  year: 2014
  ident: 1050_CR69
  publication-title: Mol. Ther. - Nucleic Acids
  doi: 10.1038/mtna.2014.47
– volume: 234
  start-page: 16861
  year: 2019
  ident: 1050_CR85
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.28368
SSID ssj0025474
Score 2.6734526
SecondaryResourceType review_article
Snippet As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and clinical...
Abstract As a type of short noncoding RNAs, microRNA (miRNA) undoubtedly plays a crucial role in cancer development. Since the discovery of the identity and...
SourceID nrf
doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1314
SubjectTerms 631/67/1059
692/308/153
Antineoplastic Agents - therapeutic use
Biomarkers
Biomarkers, Tumor - genetics
Biomedical and Life Sciences
Biomedicine
Cancer research
Cancer therapies
Clinical trials
Diagnosis
Drug development
Drug efficacy
Humans
Medical Biochemistry
Medical research
MicroRNAs
MicroRNAs - genetics
miRNA
Molecular Medicine
Neoplasms - diagnosis
Neoplasms - genetics
Neoplasms - therapy
Review
Review Article
Stem Cells
Therapeutic targets
Tumors
생화학
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEB_0BPFF9M6P6ikRxRct122TNPVFVvE4hd0H8WDfQpuk53Lanm3v4f57Z9J0l_XjYOlCm0Lb-fpNZvILwCvrDIJYRG6FnElMUEo0qcRh4kp03yYTJreUKC6W8uSUf1mJVZhw60Nb5eQTvaO2raE58iN0o5xnCK-z9xe_Yto1iqqrYQuNm3CLqMtIq_PVNuES3LMwzxBixBnGrbBoJsnUUY8nc2q_pW6iRCRxsROYPH8_hpumq_8FPf_uoPyjjOqj0_E9uBtgJZuPenAfbrhmHw7mDabUP6_Ya-YbPf0M-j7cXoR6-gEsF9SP93U5f8cG3xzL1g2bFksyv6NHz9qaGdKNjtmxL2_ds7KxbFy6dcX6YaKbeACnx5--fTyJww4LscG8Y8C8UdmqQHeduaI0qeF4EKlT3NTCM_1JKVCaFuN8rsxMycrkyqWydnmRWumyh7DXtI17DCyty5rLihi7SEqyQqBiK1Oklc0xUpoIZtPn1SbQj9MuGD-0L4NnSo8i0SgS7UWiiwjebO65GMk3rh39gaS2GUnE2f5E253pYIe6tEIZ6RLlqpo7lRdOWsFL_KFj4jyJ4CXKXJ-btb-f_s9afd5pTC8-a0JjBeacERxOOqGDzfd6q6ERvNhcRmulEkzZuPbSjyEKw4yLCB6NKrR53gzBHDEERqB2lGvnhXavNOvvnhGc6vkc3XUEbyc93D7X_7_Yk-tf4yncSb2BUHPyIewN3aV7hhBsqJ57O_sNtlko_w
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature HAS Fully OA
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6VVkJcqtLyCC3ICMQFVmT9isMtIKqy0u4BqNSbldhOWbVNqiQ99N8zdh5ooSAhRRtpY0t2ZsYzk_n8GeC1dQaDWIzcUjmXmKDkaFKxw8TV030bJkxifaK4XMmTU744E2dbQMe9MAG0HygtwzI9osPet3NKEw-X9eifWMSz9B7seKp21O2dLFt8W0xpluAJH7bHxEzd0XPDBQWmfnQsVVPeFWT-iZX8rWAa_NDxHuwOASTJ-iE_hC1X7cNBhrOpr27JGxIgneFb-T7cXw6V8wNYLT3y7usq-0C6AIMl64qM2yJJOLujJXVJjNeChtgegbduSV5Z0m_SuiVtNxJLPILT48_fP53MhrMUZgYzjA4zRGWLFBdm5tLcUMPxR1CnuClF4PSTUqDcLHr0RJm5koVJlKOydElKrXTsMWxXdeWeAqFlXnJZeG4uhumOLDAksYVJaWET9Ikmgvn4erUZiMb9eReXOhS8mdK9SDSKRAeR6DSCt1Of655m45-tP3qpTS09RXb4o27O9aAyOrdCGeli5YqSO5WkTlrBc7xwCeI8juAVylxfmHXo7-_ntb5oNCYSX7SPu1LMLiM4GnVCD9bdanTpPMydRfByeox26YsteeXqm9DGkxUyLiJ40qvQNF6GYZvnAoxAbSjXxoQ2n1TrH4H721fuOS7MEbwb9fDXuP7-xp79X_NDeECDwXhY8hFsd82Ne47BV1e8GKztJ0I2Jig
  priority: 102
  providerName: Springer Nature
Title MicroRNA: trends in clinical trials of cancer diagnosis and therapy strategies
URI https://link.springer.com/article/10.1038/s12276-023-01050-9
https://www.ncbi.nlm.nih.gov/pubmed/37430087
https://www.proquest.com/docview/2844434873
https://www.proquest.com/docview/2845103345
https://pubmed.ncbi.nlm.nih.gov/PMC10394030
https://doaj.org/article/ad58c6e08ebf4e879e6d54a54a794440
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002984781
Volume 55
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Experimental and Molecular Medicine, 2023, 55(0), , pp.1314-1321
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwED_BkBAvE9v4CIzKCMQLVEsTf4W3rNo0KrVCg0l9sxLbGdXAnZrsYf89Zycp6xjwghQlUuJItu8ud7_c-WeAt8ZqDGIxcsv4iCNAKdCkYovA1dN965RpYTxQnM74yRmdzNn8xlZfviaspQduJ-6gMExqbmNpy4paKTLLDaMFHqhJlAa0jj6vB1Md1GJU0G6JTJzKg3qUJMIX2_raoZjFw2zDDQW2fnQublXdFWj-Xi95K2kafNHxY9jugkiSt53fgXvW7cJe7hBA_7gm70go6wz_y3fh4bTLnu_BbOqr705n-UfShFJYsnCkXxpJwv4dNVlWRHtNWBHTVuEtalI4Q9qFWtekbnpyiSdwdnz0dXwy7PZTGGpEGQ2iRGnKDD_Oqc0KnWiKJ5ZYSXXFAq8f5wxlZ9CrC6lHkpdaSJvwyoosMdymT2HLLZ19DiSpiory0vNzpQh5eIlhiSl1lpRGoF_UEYz66VW6Ixv3e158VyHpnUrVikShSFQQicoieL9-57Kl2vhr60MvtXVLT5MdbqDyqE551L-UJ4I3KHN1oRfhfX89X6qLlUIw8Un52CtDhBnBfq8TqrPwWqFbp2HsaQSv14_RNn3CpXB2eRXaeMLClLIInrUqtO5viqGb5wOMQG4o18aANp-4xbfA_-2z9xQ_zhF86PXwV7_-PGMv_seMvYRHSTAjX7C8D1vN6sq-wrCsKQdwX8zFAB7k-eTLBK-HR7PPp3h3zMeDYJ0_AT2BNMU
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9NAEB6VIgEvCFoOQ4FFHC_UqmOv12skhMJRJbTJA2qlvC327rpEBbvEqVD-FL-RmbWdKBx9qxQlko_Iu3N94539BuC5sRpBLCK3VPQEJigZmlRgMXElum8dxToxlCiOxmJwzD9N4skG_Or2wlBZZecTnaM2laZ35HvoRjmPEF5Hb89--NQ1ilZXuxYajVoc2MVPTNnqN8MPKN8XYbj_8ej9wG-7CvgasfYccyVp8hRdVGTTTIea41ccWsl1ETt2OyFiHIHB2JZI3ZMi14m0oShskoZG2Aj_9wpcxcAbULKXTFYJXswd63MPIY0fYZxsN-kEkdyr8WBC5b5UvRTEgZ-uBULXLwDDWzkr_gV1_67Y_GPZ1kXD_Vtws4WxrN_o3W3YsOUWbPdLTOG_L9hL5gpL3Rv7Lbg2atfvt2E8ovq_z-P-azZ3xbhsWrJucyZzHURqVhVMky7OmGnqAKc1y0rDmq1iC1bPO3qLO3B8KXN_FzbLqrT3gYVFVnCRE0MYaYXIERiZXKdhbhKMzNqDXje9Srd059R145tyy-6RVI1IFIpEOZGo1INXy3vOGrKPC69-R1JbXklE3e5ANTtRrd2rzMRSCxtImxfcyiS1wsQ8ww86Qs4DD56hzNWpnrr76fekUqczhenMUBH6SzHH9WCn0wnV-pharSzCg6fL0-gdaMknK2117q4hysSIxx7ca1Ro-bwRgkdiJPRArinX2oDWz5TTr46BnOoHOIYHD3Y7PVw91_9n7MHFw3gC1wdHo0N1OBwfPIQboTMWKozegc357Nw-Qvg3zx87m2Pw5bKN_DefpWYg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4anTTxgmDjEhhgxOUFqqaJ4zhICHVs1cpoNU1M2ptJbGdUg2Q0nVD_Gr-Oc5ykU7nsbVLVSrlUsc_tO_HncwBeGKsRxCJyS0RfYIKSokn5FhNXKvetw0jHhhLF8UTsH_OPJ9HJGvxq98IQrbL1ic5Rm1LTO_IeulHOQ4TXYS9vaBGHu8P35z-61EGKVlrbdhq1ihzYxU9M36p3o12U9csgGO59_rDfbToMdDXi7jnmTdJkCbqr0CapDjTHryiwkus8cpXuhIhwNAbjXCx1X4pMx9IGIrdxEhhhQ_zfG7AeU1bUgfWdvcnh0TLdi7irAd1HgNMNMWo2W3b8UPYqPBgT-Ze4TH7kd5OVsOi6B2CwK2b5v4Dv3_zNPxZxXWwc3oZbDahlg1oL78CaLTZha1BgQv99wV4xRzN17-83YWPcrOZvwWRMbMCjyeAtmztqLpsWrN2qyVw_kYqVOdOkmTNmalbgtGJpYVi9cWzBqnlb7OIuHF_L7N-DTlEW9gGwIE9zLjKqF0Y6IjKESSbTSZCZGOO09qDfTq_STfFz6sHxTblF-FCqWiQKRaKcSFTiwevlPed16Y8rr94hqS2vpLLd7kA5O1WNF1CpiaQW1pc2y7mVcWKFiXiKH3SLnPsePEeZqzM9dffT72mpzmYKk5uRIiyYYMbrwXarE6rxOJW6tA8Pni1Po6-gBaC0sOWFu4YKKIY88uB-rULL5w0RSlJ9Qg_kinKtDGj1TDH96uqRE5uAY7Dw4E2rh5fP9f8Ze3j1MJ7CBhq4-jSaHDyCm4GzFWJJb0NnPruwjxELzrMnjdEx-HLddv4b095ruw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MicroRNA%3A+trends+in+clinical+trials+of+cancer+diagnosis+and+therapy+strategies&rft.jtitle=Experimental+%26+molecular+medicine&rft.au=Taewan+Kim&rft.au=Carlo+M.+Croce&rft.date=2023-07-01&rft.pub=Nature+Publishing+Group&rft.eissn=2092-6413&rft.volume=55&rft.issue=7&rft.spage=1314&rft.epage=1321&rft_id=info:doi/10.1038%2Fs12276-023-01050-9&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_ad58c6e08ebf4e879e6d54a54a794440
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2092-6413&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2092-6413&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2092-6413&client=summon